Home/Healios/Hardy TS Kagimoto, MD
HT

Hardy TS Kagimoto, MD

Founder, Chairman and CEO

Healios

Healios Pipeline

DrugIndicationPhase
HLCM051 (MultiStem)Acute Respiratory Distress Syndrome (ARDS)Phase 2/3
iPSC-derived RPE cellsAge-Related Macular DegenerationPreclinical/Research
eNK CellsSolid Tumors (Mesothelioma, Lung, HCC, Gastric)Preclinical/Research